Inicio
Resultado de la búsqueda
5 búsqueda de la palabra clave 'chemotherapy'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigaciónCardio-oncology clinical assessment and screening in patients undergoing high toxicity chemotherapy: a retrospective cohort study / Andrés Felipe Miranda Arboleda ; Juan Guillermo Gamboa Arroyave
Título : Cardio-oncology clinical assessment and screening in patients undergoing high toxicity chemotherapy: a retrospective cohort study Tipo de documento : documento electrónico Autores : Andrés Felipe Miranda Arboleda, ; Juan Guillermo Gamboa Arroyave, Fecha de publicación : 2022 Títulos uniformes : Cureus Idioma : Inglés (eng) Palabras clave : cardio-oncology solid tumors hematological malignancies chemotherapy cardiotoxicity Resumen : Objective: To describe the clinical characteristics and cardio-oncological assessment in patients undertaking highly toxic chemotherapy and/or chest radiotherapy in a high-complexity hospital. Methods: A single-center retrospective cohort study was carried out between January 1st, 2017 and December 31st, 2019. The medical records of patients with solid or hematological neoplasms were reviewed. Descriptive information was obtained on demographic characteristics, chemotherapeutic agents, pre-chemotherapy cardiovascular (CV) evaluation, and CV outcomes. The risk of complications was assessed using the Mayo Clinic risk score. Results: A total of 499 patients were included, the most common neoplasm was non-Hodgkin's lymphoma (21.6%), followed by breast cancer (19.4%). A very high risk of cardiotoxicity was present in 44.1% and 90% were not evaluated by cardiology. Pre-chemotherapy echocardiography was obtained in 65%, but only 19.4% underwent echocardiographic control after finishing chemotherapy. The most frequent CV outcomes were chemotherapy-related systolic dysfunction (4.4%) and rhythm disturbances (2.8%), with atrial fibrillation and atrial flutter being the most frequent arrhythmias. Conclusion: Despite the recognized CV toxicity of chemotherapeutic drugs, the majority of patients receiving highly toxic regimens at high risk of CV complications are not previously evaluated by a cardiologist and the CV workup was not routinely used in our study. The implementation of cardio-oncology programs will facilitate the identification of high-risk patients, aiming to detect and treat complications early. Mención de responsabilidad : Carlos A. Regino, Jonathan Cardona-Vélez, Jesus D. Bello Simanca, Andres F. Miranda Arboleda, Juan G. Gamboa Arroyave, Fabian Jaimes DOI (Digital Object Identifier) : 10.7759/cureus.32513 Derechos de uso : CC BY En línea : https://www.cureus.com/articles/127878-cardio-oncology-clinical-assessment-and-s [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6076 Cardio-oncology clinical assessment and screening in patients undergoing high toxicity chemotherapy: a retrospective cohort study [documento electrónico] / Andrés Felipe Miranda Arboleda, ; Juan Guillermo Gamboa Arroyave, . - 2022.
Obra : Cureus
Idioma : Inglés (eng)
Palabras clave : cardio-oncology solid tumors hematological malignancies chemotherapy cardiotoxicity Resumen : Objective: To describe the clinical characteristics and cardio-oncological assessment in patients undertaking highly toxic chemotherapy and/or chest radiotherapy in a high-complexity hospital. Methods: A single-center retrospective cohort study was carried out between January 1st, 2017 and December 31st, 2019. The medical records of patients with solid or hematological neoplasms were reviewed. Descriptive information was obtained on demographic characteristics, chemotherapeutic agents, pre-chemotherapy cardiovascular (CV) evaluation, and CV outcomes. The risk of complications was assessed using the Mayo Clinic risk score. Results: A total of 499 patients were included, the most common neoplasm was non-Hodgkin's lymphoma (21.6%), followed by breast cancer (19.4%). A very high risk of cardiotoxicity was present in 44.1% and 90% were not evaluated by cardiology. Pre-chemotherapy echocardiography was obtained in 65%, but only 19.4% underwent echocardiographic control after finishing chemotherapy. The most frequent CV outcomes were chemotherapy-related systolic dysfunction (4.4%) and rhythm disturbances (2.8%), with atrial fibrillation and atrial flutter being the most frequent arrhythmias. Conclusion: Despite the recognized CV toxicity of chemotherapeutic drugs, the majority of patients receiving highly toxic regimens at high risk of CV complications are not previously evaluated by a cardiologist and the CV workup was not routinely used in our study. The implementation of cardio-oncology programs will facilitate the identification of high-risk patients, aiming to detect and treat complications early. Mención de responsabilidad : Carlos A. Regino, Jonathan Cardona-Vélez, Jesus D. Bello Simanca, Andres F. Miranda Arboleda, Juan G. Gamboa Arroyave, Fabian Jaimes DOI (Digital Object Identifier) : 10.7759/cureus.32513 Derechos de uso : CC BY En línea : https://www.cureus.com/articles/127878-cardio-oncology-clinical-assessment-and-s [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6076 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001920 AC-2022-084 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-084Adobe Acrobat PDF
Título : 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Chemotherapy neoplasms neuroendocrine tumors pituitary temozolomide Resumen : Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Leon D Ortiz, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Aug;25(8):T159-T169. DOI (Digital Object Identifier) : 10.1530/ERC-18-0015 PMID : 29535142 En línea : https://erc.bioscientifica.com/view/journals/erc/25/8/ERC-18-0015.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4186 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update [documento electrónico] / Luis Vicente Syro Moreno, . - 2018.
Obra : Endocrine Related Cancer
Idioma : Inglés (eng)
Palabras clave : Chemotherapy neoplasms neuroendocrine tumors pituitary temozolomide Resumen : Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Leon D Ortiz, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Aug;25(8):T159-T169. DOI (Digital Object Identifier) : 10.1530/ERC-18-0015 PMID : 29535142 En línea : https://erc.bioscientifica.com/view/journals/erc/25/8/ERC-18-0015.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4186 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000800 AC-2018-087 Archivo digital Producción Científica Artículos científicos Disponible
Título : Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective Tipo de documento : documento electrónico Autores : Carlos Humberto Martínez González, Fecha de publicación : 2018 Títulos uniformes : Medical Oncology Idioma : Inglés (eng) Palabras clave : Chemotherapy hormonal therapy latin america radium-223 mCRPC Resumen : Prostate cancer is a significant burden and cause of mortality in Latin America. This article reviews the treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) and provides consensus recommendations to assist Latin American prostate cancer specialists with clinical decision making. A multidisciplinary expert panel from Latin America reviewed the available data and their individual experience to develop clinical consensus opinions for the use of life-prolonging agents in mCRPC, with consideration given to factors influencing patient selection and treatment monitoring. There is a lack of level 1 evidence for the best treatment sequence or combinations in mCRPC. In this context, consensus recommendations were provided for the use of taxane-based chemotherapies, androgen receptor axis-targeted agents and targeted alpha therapy, for patients in Latin America. Prostate-specific antigen (PSA) changes alone, during treatment, should be treated with caution; PSA may not be a suitable biomarker for radium-223. Bone scans and computed tomography are the standard imaging modalities in Latin America. Imaging should be prompted during treatment where symptomatic decline and/or significant worsening of laboratory evaluations are reported, or where a course of therapy has been completed and another antineoplastic agent is under consideration. Recommendations and guidance for treatment options in Latin America are provided in the context of country-level variable access to approved agents and technologies for treatment monitoring. Patients should be treated with the purpose of prolonging overall survival and preserving quality of life through increasing the opportunity to administer all available life-prolonging therapies when appropriate. Mención de responsabilidad : Juan Pablo Sade, Carlos Alberto Vargas Báez, Martin Greco, Carlos Humberto Martínez, Miguel Ángel Álvarez Avitia, Carlos Palazzo, Narciso Hernández Toriz, Patricia Isabel Bernal Trujillo, Diogo Assed Bastos, Fabio Augusto Schutz, Santiago Bella, Lucas Nogueira, Neal D Shore Referencia : Med Oncol. 2018 Mar 19;35(4):56. DOI (Digital Object Identifier) : 10.1007/s12032-018-1105-8 PMID : 29556815 En línea : https://link.springer.com/article/10.1007%2Fs12032-018-1105-8 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4184 Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective [documento electrónico] / Carlos Humberto Martínez González, . - 2018.
Obra : Medical Oncology
Idioma : Inglés (eng)
Palabras clave : Chemotherapy hormonal therapy latin america radium-223 mCRPC Resumen : Prostate cancer is a significant burden and cause of mortality in Latin America. This article reviews the treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) and provides consensus recommendations to assist Latin American prostate cancer specialists with clinical decision making. A multidisciplinary expert panel from Latin America reviewed the available data and their individual experience to develop clinical consensus opinions for the use of life-prolonging agents in mCRPC, with consideration given to factors influencing patient selection and treatment monitoring. There is a lack of level 1 evidence for the best treatment sequence or combinations in mCRPC. In this context, consensus recommendations were provided for the use of taxane-based chemotherapies, androgen receptor axis-targeted agents and targeted alpha therapy, for patients in Latin America. Prostate-specific antigen (PSA) changes alone, during treatment, should be treated with caution; PSA may not be a suitable biomarker for radium-223. Bone scans and computed tomography are the standard imaging modalities in Latin America. Imaging should be prompted during treatment where symptomatic decline and/or significant worsening of laboratory evaluations are reported, or where a course of therapy has been completed and another antineoplastic agent is under consideration. Recommendations and guidance for treatment options in Latin America are provided in the context of country-level variable access to approved agents and technologies for treatment monitoring. Patients should be treated with the purpose of prolonging overall survival and preserving quality of life through increasing the opportunity to administer all available life-prolonging therapies when appropriate. Mención de responsabilidad : Juan Pablo Sade, Carlos Alberto Vargas Báez, Martin Greco, Carlos Humberto Martínez, Miguel Ángel Álvarez Avitia, Carlos Palazzo, Narciso Hernández Toriz, Patricia Isabel Bernal Trujillo, Diogo Assed Bastos, Fabio Augusto Schutz, Santiago Bella, Lucas Nogueira, Neal D Shore Referencia : Med Oncol. 2018 Mar 19;35(4):56. DOI (Digital Object Identifier) : 10.1007/s12032-018-1105-8 PMID : 29556815 En línea : https://link.springer.com/article/10.1007%2Fs12032-018-1105-8 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4184 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000798 AC-2018-085 Archivo digital Producción Científica Artículos científicos Disponible
Título : Successful treatment of pulmonary invasive fungal infection by Penicillium non-marneffei in lymphoblastic lymphoma: case report and literature review Tipo de documento : documento electrónico Autores : Isabel Cristina Ramírez Sánchez, ; Alicia Inés Hidrón Botero, ; Ricardo Andrés Cardona Quiceno, Fecha de publicación : 2018 Títulos uniformes : Clinical Case Reports Idioma : Inglés (eng) Palabras clave : Chemotherapy immunosuppression leukemia lymphoma Penicillium non-marneffei transplant Resumen : Penicillium non‐marneffei species rarely cause disease in humans and are encountered most commonly in the clinical laboratory as culture contaminants; however, recently they have emerged as opportunistic pathogens in immunocompromised hosts; therefore, it should not be routinely disregarded without a thorough investigation, especially if normally sterile sites are involved. Mención de responsabilidad : Isabel Ramírez, Alicia Hidrón, Ricardo Cardona Referencia : Clinical Case Reports 2018;6(6):1153-7. DOI (Digital Object Identifier) : 10.1002/ccr3.1527 PMID : 29881585 Derechos de uso : CC BY En línea : https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.1527 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4158 Successful treatment of pulmonary invasive fungal infection by Penicillium non-marneffei in lymphoblastic lymphoma: case report and literature review [documento electrónico] / Isabel Cristina Ramírez Sánchez, ; Alicia Inés Hidrón Botero, ; Ricardo Andrés Cardona Quiceno, . - 2018.
Obra : Clinical Case Reports
Idioma : Inglés (eng)
Palabras clave : Chemotherapy immunosuppression leukemia lymphoma Penicillium non-marneffei transplant Resumen : Penicillium non‐marneffei species rarely cause disease in humans and are encountered most commonly in the clinical laboratory as culture contaminants; however, recently they have emerged as opportunistic pathogens in immunocompromised hosts; therefore, it should not be routinely disregarded without a thorough investigation, especially if normally sterile sites are involved. Mención de responsabilidad : Isabel Ramírez, Alicia Hidrón, Ricardo Cardona Referencia : Clinical Case Reports 2018;6(6):1153-7. DOI (Digital Object Identifier) : 10.1002/ccr3.1527 PMID : 29881585 Derechos de uso : CC BY En línea : https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.1527 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4158 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000772 AC-2018-059 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2018-059.pdfAdobe Acrobat PDF
Título : Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : Alkylating agents chemotherapy DNA repair neoplasms neuroendocrine tumors O(6)-Methylguanine-DNA Methyltransferase pituitary temozolomide Resumen : Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2018 Jun 15;9:318 DOI (Digital Object Identifier) : 10.3389/fendo.2018.00318 PMID : 29963012 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4163 Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions [documento electrónico] / Luis Vicente Syro Moreno, . - 2018.
Obra : Frontiers in Endocrinology
Idioma : Inglés (eng)
Palabras clave : Alkylating agents chemotherapy DNA repair neoplasms neuroendocrine tumors O(6)-Methylguanine-DNA Methyltransferase pituitary temozolomide Resumen : Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2018 Jun 15;9:318 DOI (Digital Object Identifier) : 10.3389/fendo.2018.00318 PMID : 29963012 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4163 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000777 AC-2018-064 Archivo digital Producción Científica Artículos científicos Disponible
